Preferred Events
4th Annual NGS Seminar – 2021 Digital Edition
14 September, 2021
16:00-19:00 CST | 10:00 AM-01:00 PM EST | 07:00-10:00 AM PST
The impact of COVID-19 has highlighted the biopharmaceutical industry’s need for fast & innovative solutions to accelerate the development and production of new therapies. Next-generation sequencing (NGS) is a performant, validated, and secure method that brings significant advantages.
We are happy to gather industry experts to discuss strategies around NGS adoption to answer the need for rapid and robust testing and ensure the product’s and patients’ safety.
Digital Event
Why Participate
Meet experts to discuss NGS solutions to:
- Improve QC testing of biologics
- Reduce time to market
- Share data with your peers
- Improve patient safety
Who Should Register?
Biologics developers and manufacturers for:
- Cell & gene therapy
- Vaccines
- Therapeutic proteins & antibodies
- Blood and blood-derived products
Detailed Program
Use of NGS to replace animal tests for the viral safety of biologics exclusive session:
Chairman: Horst Ruppach, PhD – Scientific & Portfolio Director, Biologics Testing Solutions at Charles River
- The In Vivo Adventitious Virus Assay and Next Generation Sequencing: A Survey of the Biopharmaceutical Industry – Paul W. Barone, PhD | Director of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), Massachusetts Institute of Technology
- Evaluation of RNA Next Generation Sequencing to Replace In Vivo Tests for Assessing the Viral Safety of Cells Improve QC Testing of Biologics
- Pascale Beurdeley, PhD | Chief Scientific Officer at PathoQuest
- Marc Eloit, DVM, PhD – Founder and Scientific Advisor, PathoQuest | Head of “Pathogen Discovery Laboratory, Institut Pasteur
- A Biomanufacturing Association’s Perspective of the ICH Q5(A) Guideline Revision – Marie Murphy, PhD | EFPIA Representative from ICHQ5A(R2) Guideline Revision EWG
Focus on the industry considerations session:
- New technologies and new application around NGS technology
- Colette Côte, PhD | Chief Portfolio Officer & US General Manager at PathoQuest
- Pascale Beurdeley, PhD | Chief Scientific Officer at PathoQuest
- Innovation Interactive Working session
1 study, 2 companies, 3 minutes, 4 experts to summarize this session
Our Speakers
Invitation-only webinar
If you wish to attend or have more information about this exclusive webinar please send us a request through this form.
blabla